Keynote lecture by Myriam Chalabi at #ESMOGI24 ☑️ is there room for #immunotherapy in MSS colorectal cancer❓

#ESMOGI24: Do recent advances offer hope for mismatch repair-proficient and MSS #CRC pts who have a lower mutational burden and have historically been less responsive to immunotherapy? Read the opinion by Myriam Chalabi on #ESMODailyReporter to find out 📌ow.ly/Xqzl50SqFST

Beautiful discussion by Chiara Cremolini on therapeutic options for patients with #CRC from liver transplant to immunotherapy to later line options #ESMOGI24 #ESMOAmbassadors ESMO - Eur. Oncology

QoL preserved in CM8HW: Nivo+Ipi in MSI-H mCRC @ESMO GI

Keynote address at #ESMOGI24 with superstar Myriam Chalabi - Immunotherapy for MSS-CRC: The last frontier ESMO - Eur. Oncology OncoAlert The Netherlands Cancer Institute

Final part of the ESMO - Eur. Oncology Leaders Generation Programme ‘23-24 - Jon Lim Ilaria Colombo Marc Oliva Valentina Gambardella Brent O'Carrigan Elie Rassy oncodaily.com/91864.html #Cancer #ESMO24 #OncoDaily #Oncology

Neoadjuvant regimens in rectal cancer by ESMO Guideline risk groups @ESMO GI

TNT approaches in rectal cancer @ESMO GI

I think it was clear during #ESMOGI24 that ESMO - Eur. Oncology supports #GastrointestinalCancers and Andres Cervantes made it clear in his closing remarks. Examples 👉ESMO Guidelines in GI 👉Living guidelines 👉MCBS 👉Dedicated conference and journal #ESMOAmbassadors

ESMO Reimbursement Model workshop, Lugano 2024 ( indeed the same stairs)

❗ MDICT'24 recommendations 📢 📍 Testing 🆕 anticancer drugs before curative locoregional therapies 4️⃣ 🗝 ✔ patient engagement ✔ risk–benefit ratio & clinical/ethical equipoise ✔ randomization to ⬇️ bias & allow robust conclusions ✔ appropriate endpoints 🔓 ESMO Open 👇

Well done. It was really a pleasure to do this work together. Thank you to all those who made this possible.

#GeriatricAssessment and management are crucial for providing #PersonalisedCare. The first recommendations from the ESMO/ SIOG Cancer in the #Elderly Working Group are now available. #GeriOnc Read the #ESMODailyReporter article 📌ow.ly/fWzk50T2SsC

Looking forward to a fantastic ESMO - Eur. Oncology #esmo24 with fantastic speakers, excellent content, collaboration, exchange, mentorship & networking! Andres Cervantes George Pentheroudakis silke gillessen Tom Powles Toni Choueiri, MD FabriceAndre Matteo Lambertini, MD PhD Laurence Albiges ylt Shilpa Gupta OncoAlert

Screening for Tumour-Agnostic potential and rethinking drug development at ESMO - European Society for Medical Oncology

🚨🥁 Hot off the press 👉 Presenting to the world a future framework for Tissue agnostic drug development - Special article published Annals of Oncology –an X 'torial for this major milestone in #precisionMedicine ✅1/n - “The ESMO Tumour-Agnostic Classifier and Screener

Advances in #PrecisionOncology are moving the field towards biology-based #CancerCare: ESMO is supporting the change with a series of tailored resources for medical oncologists. Read FabriceAndre interview in the #ESMODailyReporter 👉ow.ly/Sn4350T7ptt

The ETAC screener is a simple tool to detect tumour-agnostic potential of a cancer therapy. Emphasis on “potential”. So, if the potential is there, further clinical validation would be required.

Following a drug screening positive by ETAC-S, we propose a research and regulatory framework for validation/graduation of tumour-agnostic therapies and biomarkers.

No evidence for OXP benefit when added on top of FP in the adjuvant tx of high risk stage II CC